Business
Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association
Findings derived from Afirma Xpression Atlas analysis of company’s extensive biorepository of thyroid nodule fine needle aspiration samples SOUTH SAN
About this update from Veracyte, Inc.
[{"type":"text","content":"\nFindings derived from Afirma Xpression Atlas analysis of company’s extensive biorepository of thyroid nodule fine needle aspiration samples\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nVeracyte, Inc. (Nasdaq: VCYT) announced today that new data advancing the understanding of genomic alterations – specifically, NTRK, RET, BRAF and ALK fusions – that are targeted by new precision medicine therapies for thyroid cancer will be presented at the 89th Annual Meeting of the American Thyroid Association, which will be held October 30-November 3, 2019 in Chicago. The findings will be presented in three posters and are derived from Afirma® Xpression Atlas testing of Veracyte’s extensive biorepository of fine needle aspiration (FNA) samples from patients undergoing evaluation for thyroid cancer.\n\n\n“We believe our extensive collection of thyroid nodule FNA samples with RNA whole-transcriptome sequencing data uniquely enables us to broaden the scientific understanding of the role of key gene alterations in thyroid cancer,” said Richard T. Kloos, M.D., senior medical director, endocrinology, at Veracyte. “Moreover, as the role of precision medicine in thyroid cancer treatment expands, our Afirma Xpression Atlas helps inform physicians’ treatment decisions for their patients with thyroid cancer using the same minimally invasive sample that is used for initial diagnosis with the Afirma Genomic Sequencing Classifier.”\n\n\nFollowing are details of the presentations, which will be presented in the Sheraton Grand Chicago Exhibit Hall:\n\n\n\n\nTitle:\n\n\n\n\n\nPositive Predictive Value of NTRK, RET, BRAF and ALK Fusions in Bethesda III/IV Thyroid Fine-Needle Aspirates\n\n\n\n\n\nPresenter:\n\n\n\n\n\nBrendan C. Stack, M.D., University of Arkansas for Medical Sciences\n\n\n\n\n\nDate/Time:\n\n\n\n\n\nFriday, Nov. 1, 10:05 a.m.-11:00 a.m. and 12:15 p.m.-1:30 p.m. (Central Time)\n\n\n\n\n\nPoster #:\n\n\n\n\n\nShort Call Poster 55\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n\n\nTitle:\n\n\n\n\n\nIdentification of Rare, Canonically Mutually Exclusive Variants in Thyroid FNAs\n\n\n\n\n\nPresenter:\n\n\n\n\n\nBryan R. Haugen, M.D., University of Colorado School of Medicine\n\n\n\n\n\nDate/Time:\n\n\n\n\n\nSaturday, Nov. 2, 10:05 a.m.-11:00 a.m. and 11:45 a.m.-1:00 p.m. (Central Time)\n\n\n\n\n\nPoster #\n\n\n\n\n\n461\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n\...